These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Expression of the cdx2 gene in benign intestinal-type mucinous ovarian tumors]. Gaggero G; Sola S; Mora M; Fulcheri E Pathologica; 2003 Aug; 95(4):185-91. PubMed ID: 14577202 [TBL] [Abstract][Full Text] [Related]
3. Expression of REG4 in ovarian mucinous tumors. Huang Q; Chen X; Lu W; Lai M; Lu B Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):295-301. PubMed ID: 23958547 [TBL] [Abstract][Full Text] [Related]
4. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type. Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943 [TBL] [Abstract][Full Text] [Related]
6. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Groisman GM; Meir A; Sabo E Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours. Strickland S; Parra-Herran C Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609 [TBL] [Abstract][Full Text] [Related]
10. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447 [TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical profile of colorectal and ovarian carcinomas--examination with cytokeratin 7, cytokeratin 20, beta catenin and cDX 2]. Porjazova E; Zaprjanov Z; Batashki I; Markova D; Milchev N Akush Ginekol (Sofiia); 2009; 48(2):7-12. PubMed ID: 20198769 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive immunohistochemical analysis of the gastrointestinal and Müllerian phenotypes of 139 ovarian mucinous cystadenomas. Halimi SA; Maeda D; Ushiku-Shinozaki A; Goto A; Oda K; Osuga Y; Fujii T; Ushiku T; Fukayama M Hum Pathol; 2021 Mar; 109():21-30. PubMed ID: 33275953 [TBL] [Abstract][Full Text] [Related]
13. Histochemical analysis of estrogen and progesterone receptors and gastric-type mucin in mucinous ovarian tumors with reference to their pathogenesis. Shiohara S; Shiozawa T; Shimizu M; Toki T; Ishii K; Nikaido T; Fujii S Cancer; 1997 Sep; 80(5):908-16. PubMed ID: 9307191 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory role of prohibitin in human ovarian epithelial cancer. Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933 [TBL] [Abstract][Full Text] [Related]
15. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Logani S; Oliva E; Arnell PM; Amin MB; Young RH Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251 [TBL] [Abstract][Full Text] [Related]
16. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Vang R; Gown AM; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM Am J Surg Pathol; 2006 Sep; 30(9):1130-9. PubMed ID: 16931958 [TBL] [Abstract][Full Text] [Related]
17. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039 [TBL] [Abstract][Full Text] [Related]
18. Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation. Park KJ; Bramlage MP; Ellenson LH; Pirog EC Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):8-11. PubMed ID: 18776815 [TBL] [Abstract][Full Text] [Related]
19. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature. Ates Ozdemir D; Usubutun A Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858 [TBL] [Abstract][Full Text] [Related]
20. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray. Kim MJ J Korean Med Sci; 2005 Aug; 20(4):643-8. PubMed ID: 16100458 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]